KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Gross Margin (2017 - 2025)

Aquestive Therapeutics has reported Gross Margin over the past 9 years, most recently at 153.65% for Q4 2025.

  • Quarterly results put Gross Margin at 153.65% for Q4 2025, up 9173.0% from a year ago — trailing twelve months through Dec 2025 was 87.12% (up 1817.0% YoY), and the annual figure for FY2025 was 87.12%, up 1817.0%.
  • Gross Margin for Q4 2025 was 153.65% at Aquestive Therapeutics, up from 64.82% in the prior quarter.
  • Over the last five years, Gross Margin for AQST hit a ceiling of 153.65% in Q4 2025 and a floor of 123.3% in Q2 2021.
  • Median Gross Margin over the past 5 years was 63.34% (2023), compared with a mean of 58.08%.
  • Biggest five-year swings in Gross Margin: soared 48450bps in 2021 and later crashed -3641bps in 2024.
  • Aquestive Therapeutics' Gross Margin stood at 69.62% in 2021, then fell by -28bps to 50.34% in 2022, then rose by 16bps to 58.49% in 2023, then grew by 6bps to 61.91% in 2024, then surged by 148bps to 153.65% in 2025.
  • The last three reported values for Gross Margin were 153.65% (Q4 2025), 64.82% (Q3 2025), and 54.4% (Q2 2025) per Business Quant data.